Breast cancer patients have varying prognoses and responses to treatment due to the heterogeneity of the disease. This chapter surveys the histopathological features, molecular markers, and multigene signatures used for prognosis and prediction of treatment response. The commercially available gene expression based assays for prognostication/prediction in ER+ breast cancer are briefly described and critically discussed. We analyze the underlying reasons for the comparable significance of these tests at the population level, while the tests are discordant for many individual patients. The current challenges to development of future assays are discussed.
- Intrinsic classification
- Mammaprint oncotype DX and prosigna
- Nottingham prognostic index
ASJC Scopus subject areas